Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD−L1 immunostaining: what pathologists need to know
Mohammed Akhtar, Sameera Rashid, Issam Al‐Bozom
Diagnostic Pathology (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

PD-L1 testing by immunohistochemistry in Immuno-Oncology
Semir Vranić, Zoran Gatalica
Bosnian Journal of Basic Medical Sciences (2022)
Open Access | Times Cited: 61
High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
Marie E. Robert, Josef Rüschoff, Bharat Jasani, et al.
Modern Pathology (2023) Vol. 36, Iss. 5, pp. 100154-100154
Open Access | Times Cited: 40
Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer
Melissa Y. Tjota, Jeremy P. Segal, Peng Wang
The Journal of Applied Laboratory Medicine (2024) Vol. 9, Iss. 1, pp. 76-91
Closed Access | Times Cited: 9
Targeting NaPi2b in ovarian cancer
Susana Banerjee, Ronny Drapkin, Debra L. Richardson, et al.
Cancer Treatment Reviews (2022) Vol. 112, pp. 102489-102489
Closed Access | Times Cited: 28
Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis
Timothy S. Fitzsimmons, Niharika Singh, Thomas D. J. Walker, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 22
Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?
Carlo Putzu, Stefania Canova, Panagiotis Paliogiannis, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 689-689
Open Access | Times Cited: 21
Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis
Giorgio Frega, Fernando P. Cossío, Jesús M. Bañales, et al.
Cells (2023) Vol. 12, Iss. 16, pp. 2098-2098
Open Access | Times Cited: 19
Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods
Francesca Porta, Elham Sajjadi, Konstantinos Venetis, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 7, pp. 1176-1176
Open Access | Times Cited: 18
Immunophenotypic and Gene Expression Analyses of the Inflammatory Microenvironment in High-Grade Oral Epithelial Dysplasia and Oral Lichen Planus
Andres Flores-Hidalgo, James A. Phero, Scott Steward-Tharp, et al.
Head and Neck Pathology (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 6
The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition
Hannah L. Williams, A. Frei, Thibaud Koessler, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 6
Chamuangone-enriched rice bran oil ameliorates neurodegeneration in haloperidol-induced Parkinsonian rat model via modulation of neuro-inflammatory mediators and suppression of oxidative stress markers
Badriyah S. Alotaibi, Uzma Saleem, Aqsa Ahmad, et al.
Italian Journal of Food Science (2024) Vol. 36, Iss. 2, pp. 163-180
Open Access | Times Cited: 5
Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer
Torhild Veen, Arezo Kanani, Dordi Lea, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 10, pp. 3135-3147
Open Access | Times Cited: 11
Interpretation of PD-L1 expression in gastric cancer: summary of a consensus meeting of Korean gastrointestinal pathologists
Soomin Ahn, Yoonjin Kwak, Gui Young Kwon, et al.
Journal of Pathology and Translational Medicine (2024) Vol. 58, Iss. 3, pp. 103-116
Open Access | Times Cited: 4
Regulation of PD-L1 glycosylation and advances in cancer immunotherapy
Te-An Lee, En-Yun Tsai, Shou-Hou Liu, et al.
Cancer Letters (2025), pp. 217498-217498
Closed Access
Exploring Immune Checkpoint Inhibitors: Focus on PD-1/PD-L1 Axis and Beyond
Durre Aden, Samreen Zaheer, Niti Sureka, et al.
Pathology - Research and Practice (2025) Vol. 269, pp. 155864-155864
Closed Access
PD-L1/PD-1 Expression in the Treatment of Oral Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: An Overview of Reviews
Huda Moutaz Asmael Al‐Azzawi, Syed Ameer Hamza, Rita Paolini, et al.
Journal of Personalized Medicine (2025) Vol. 15, Iss. 4, pp. 126-126
Open Access
PD‐L1 Scoring Models for Non‐Small Cell Lung Cancer in China: Current Status, AI‐Assisted Solutions and Future Perspectives
Ziling Huang, Shen Wang, Jiansong Zhou, et al.
Thoracic Cancer (2025) Vol. 16, Iss. 7
Open Access
Immunoinformatics based designing of a multi-epitope cancer vaccine targeting programmed cell death ligand 1
Syed Sahajada Mahafujul Alam, Showkat Ahmad Mir, Arijit Samanta, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Molecular Pathology of Gastric Cancer
Moonsik Kim, An Na Seo
Journal of the Korean Gastric Cancer Association (2022) Vol. 22, Iss. 4, pp. 264-264
Open Access | Times Cited: 17
Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy - a review
Marek Zdrenka, Adam Kowalewski, Navid Ahmadi, et al.
Biomolecules and Biomedicine (2023)
Open Access | Times Cited: 10
Update on Classic and Novel Approaches in Metastatic Triple-Negative Breast Cancer Treatment: A Comprehensive Review
Salvatore Greco, Nicolò Fabbri, Riccardo Spaggiari, et al.
Biomedicines (2023) Vol. 11, Iss. 6, pp. 1772-1772
Open Access | Times Cited: 9
A Pipeline for Evaluation of Machine Learning/Artificial Intelligence Models to Quantify Programmed Death Ligand 1 Immunohistochemistry
Beatrice S. Knudsen, Alok Jadhav, Lindsey J. Perry, et al.
Laboratory Investigation (2024) Vol. 104, Iss. 6, pp. 102070-102070
Open Access | Times Cited: 3
Cutting-Edge Platforms for Analysis of Immune Cells in the Hepatic Microenvironment—Focus on Tumor-Associated Macrophages in Hepatocellular Carcinoma
Daniel Millián, Ómar A. Saldarriaga, Timothy G. Wanninger, et al.
Cancers (2022) Vol. 14, Iss. 8, pp. 1861-1861
Open Access | Times Cited: 15
Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment
Huawei Li, Jia You, Yuanfeng Wei, et al.
Phytomedicine (2023) Vol. 123, pp. 155189-155189
Closed Access | Times Cited: 8
The Programmed Cell Death Ligand 1 and Lipocalin 2 Expressions in Primary Breast Cancer and Their Associations with Molecular Subtypes and Prognostic Factors
Süheyla Ekemen, Ebru Bilir, Hagar Soultan, et al.
Breast Cancer Targets and Therapy (2024) Vol. Volume 16, pp. 1-13
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top